X

Trial Profile

Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brodalumab (Primary) ; Guselkumab
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms COBRA
Sponsors LEO Pharma

Most Recent Events

08 Jan 2024 Status changed from completed to discontinued.
11 Jan 2023 Status changed from active, no longer recruiting to completed.
23 Dec 2022 This trial has been discontinued in Netherlands (End Date: 1 Dec 2022) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com